Gapping up
In reaction to earnings/guidance:
- POWW +5.9%, CDMO +5.5%, MLKN +5.4%, AYI +2.7%
Other news:
- ASPN +41.8% (decides not to proceed with concurrent public offerings of common stock and green convertible senior notes due 2027)
- SYM +17.9% (stock offering)
- AURA +12.9% (announced that the FDA has granted Fast Track designation for belzupacap sarotalocan (AU-011), Aura's first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer)
- AVDL +9% (provides corporate update)
- OSCR +5.2% (launches its Next Best Actions engine)
- OMGA +4.9% (Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002)
- TGAN +4.8% (stock offering)
- BPMC +4.7% (announces $1.25 bln strategic financing collaborations with Sixth Street and Royalty Pharma (RPRX); Blueprint Medicines will receive $575 mln in total cash funded at close)
- SAVE +1.4% (to adjourn Special Meeting of stockholders; intends to continue discussions with Frontier (ULCC) and JetBlue (JBLU))
- BNTX +1.2% (PFE and BNTX announce new vaccine supply agreement with US govt)
- CORT +1.1% (initiates ROSELLA, a pivotal Phase 3 trial of relacorilant plus nab-paclitaxel for ovarian cancer)
- RPRX +1.1% (confirms it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (BPMC))